The role of fascin-1 in the pathogenesis, diagnosis and management of respiratory related cancers

Zhang, Naibin; Gao, Yankun; Bian, Qiang; Wang, Qianqian; Shi, Ying; Zhao, Zhankui; Yu, Honglian

doi:10.3389/fonc.2022.948110

Cited by 1 publication

(1 citation statement)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have identified the role of fascin-1 in gynecologic cancers, 16 gastrointestinal cancers, 17 and respiratory-related cancers. 18 This review aims to elucidate fascin-1 expression in urologic cancers (bladder, prostate, and kidney cancers and adrenocortical carcinoma [ACC]) and the signaling mechanisms of the fascin-1 gene in these urologic cancers. In addition, we evaluate the potential of fascin-1 as a prognostic marker and a therapeutic target, to support further studies.…”

Section: Introductionmentioning

confidence: 99%

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

Zhang,

Bian,

Gao

et al. 2023

Technol Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Human cancer statistics show that an increased incidence of urologic cancers such as bladder cancer, prostate cancer, and renal cell carcinoma. Due to the lack of early markers and effective therapeutic targets, their prognosis is poor. Fascin-1 is an actin-binding protein, which functions in the formation of cell protrusions by cross-linking with actin filaments. Studies have found that fascin-1 expression is elevated in most human cancers and is related to outcomes such as neoplasm metastasis, reduced survival, and increased aggressiveness. Fascin-1 has been considered as a potential therapeutic target for urologic cancers, but there is no comprehensive review to evaluate these studies. This review aimed to provide an enhanced literature review, outline, and summarize the mechanism of fascin-1 in urologic cancers and discuss the therapeutic potential of fascin-1 and the possibility of its use as a potential marker. We also focused on the correlation between the overexpression of fascin-1 and clinicopathological parameters. Mechanistically, fascin-1 is regulated by several regulators and signaling pathways (such as long noncoding RNA, microRNA, c-Jun N-terminal kinase, and extracellular regulated protein kinases). The overexpression of fascin-1 is related to clinicopathologic parameters such as pathological stage, bone or lymph node metastasis, and reduced disease-free survival. Several fascin-1 inhibitors (G2, NP-G2-044) have been evaluated in vitro and in preclinical models. The study proved the promising potential of fascin-1 as a newly developing biomarker and a potential therapeutic target that needs further investigation. The data also highlight the inadequacy of fascin-1 to serve as a novel biomarker for prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%